Alphabet's life science arm, Verily, is interested in embedding sensors into sneakers to monitor a person's health and movements, CNBC reported on Friday.The company has been showing off prototype designs in private meetings and hopes to attract a shoe industry partner to bring the concept to life.Watching out for weight gain, as well as detecting-sudden falls are two health related use cases for the shoes.Can the company that revolutionized search technology, do the same for, shoes?Apparently, Google's life sciences spin-off, Verily, might take a shot.On Friday, CNBC reported that the company is interested in embedding sensors into sneakers to monitor a person's health and movements.
Alphabet could be looking to seriously step up its fitness tracking game — no pun intended.According to a report from CNBC, Verily, Alphabet’s “life sciences” organization, is looking for partners to develop shoes that can track fitness by including things like the wearer’s movement and their weight.According to the report, Verily has been showing off prototypes of the design to potential partners in an attempt to attract companies who might be willing to work with it.It makes sense that Alphabet would be looking to improve its fitness tracking; Apple has largely lead the world of fitness tracking since the launch of the Apple Watch.While the likes of Fitbit still have influence, Google’s Wear OS is only now improving its fitness tracking features and still isn’t really thought of as a leader in the space.If the company were to release something like fitness-tracking shoes, it could differentiate itself from its competitors.
Verily, Alphabet's life sciences arm, said Friday that it's received FDA clearance for an ECG feature on its Verily Study Watch.Verily, part of Google parent company Alphabet, launched the Verily Study Watch in April 2017 to collect health information from clinical research participants.The watch has been used by thousands of participants in clinical research studies, according to the company.Verily says unobtrusive biosensing using devices like Study Watch could help to understand what's happening in the body at a given time, as well as how our bodies stay healthy or change with disease.One area Verily has focused on with Study Watch is cardiovascular health.The watch includes an electrocardiogram, or ECG, feature, which measures the electrical activity of the heart and can help diagnose a variety of heart conditions.
ST. LOUIS–(BUSINESS WIRE)–December 18, 2018–Life sciences venture capital firm RiverVest Venture Partners today announced the final closing of RiverVest Venture Fund IV, L.P., reaching $184.4 million in capital commitments in an oversubscribed fundraise.RiverVest Fund IV marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of Sept. 30 to $753 million.“We are pleased that Fund IV exceeded our target,” said RiverVest co-founder and managing director Jay Schmelter.“It enables us to continue executing our strategy for generating top-quartile investor returns.”Schmelter credits RiverVest’s success to the firm’s focus on developing biopharma and medical device products that treat high, unmet medical needs, while attracting a buyer or being ready for an IPO within three to five years of the initial investment.
Since being founded in 2012, uBiome has raised nearly $110 million and rocketed from a meek citizen science project to a key player on the life science venture scene.Having experienced minor digestive issues for years, I hoped to learn more about the gut bacteria thought to play a role in everything from our mental health to our ability to process fat and gluten.In recent years, scientists have called the microbiome the "forgotten organ" thanks to its emerging role in affecting everything from your mood to your risk of disease.My uBiome test results came with a significant surprise.So far, uBiome has collected microbiome samples from 250,000 customers, Richman told Business Insider in September.Having experienced mild digestive issues for years, I was excited to learn more about how the bacteria in my gut were faring.
This report studies Super Resolution Microscopes Market with SWOT analysis, Market Share, Competitive Analysis, Segmentation, Insights, Growth, Application, Trends, Market driver analysis, Revenue and PESTEL Analysis, forecast to 2022.This report focuses on top manufacturers in Global Market. Global Super Resolution Microscopes Market is anticipated to reach USD 4.8 billion by 2022.The factors that propel the growth of the super-resolution microscopes market include rising government and private initiatives, growing R funding, and increase in the usage rates of high-resolution microscopes.On the other hand, there are factors that may hamper the growth of the market including high investment cost.
Studies indicate that more than 95 per cent of researchers in the life sciences are already working with big data or plan to do so - but more than 65 per cent state that they only have minimal knowledge of bioinformatics and statistics."Many are currently lacking training and instruction in this area - that's the real bottleneck that is making broader use of data science methods difficult," says bioinformatician Dr. Björn Grüning of the University of Freiburg.He is coordinating the Galaxy Europe project, which aims to remedy this with interactive, community-based and freely-available online tutorials on data analysis in the life sciences.The participating researchers have presented their project in the journal Cell Systems.Galaxy, an open source platform enabling the analysis of big data for life sciences, can be accessed by scientists via an Internet browser.It requires no programming skills: all settings can be made using a graphic interface.
If so, then this latest Reg survey is for youStudy Dealing with regulated data and applying strict controls to comply with GxP (e.g.Good Laboratory Practice, Good Clinical Practice, etc) and privacy in an R context is nothing new to the pharmaceutical industry and broader life sciences sector.Over the past few years, though, those involved in designing, executing and interpreting the results of clinical trials, for example, have been working with more and more information sources.Meanwhile, expectations of flexibility and convenience throughout the research process have been rising, including in relation to information sharing and collaboration.Against this background, we are interested in the views of those working in life sciences on how information needs are evolving, the kinds of challenges and opportunities that are emerging, and how well traditional systems are keeping up with demands and expectations.
Shak Lakhani, the 21-year-old chief executive and co-founder of Avro Life Sciences, started researching biomaterials when he was 15 years old.Every summer and after school the teenager would travel nearly two hours by bus and train from the Richmond Hill neighborhood of Toronto where he lived to the tissue engineering lab at the University of Toronto and develop three dimensional, in-vitro models of tumors using biomaterials.For three years, Lakhani worked in the lab, before going on to study nanotechnology engineering at the University of Waterloo a short 73 miles away.A former epidemiologist who worked as a research assistant at the aptly named Hospital for Sick Children, Sarani spent his high school years working in community pharmacies before going on to graduate from the University of Waterloo with both an Honours Science degree and a doctorate in pharmacy directly from high school.Sarani and Lakhani, who’re related by marriage, first met in the Village 1 dormitory complex at the University.They formally launched the business in January 2016, a time when Lakhani said the two college students would hold “startup Sundays” where they would pitch ideas to each other in one dorm room or another on Sunday evenings, until they found an idea that seemed viable.
Today we present the third and final installment of my interview with George Church, whose Harvard lab is one of the most celebrated fountains of innovation in the world of life science.The article accompanying part one will also give you the lowdown on this experimental melding of Ars Technica’s written pages with a long-form podcast series.We start today’s installment by discussing an audacious project to resurrect the wooly mammoth—or at least certain genes of it, which allowed it to thrive in frigid regions.The modern Asian elephant is a close cousin to the mammoth, and infusing those genes into its genome could give us a hybrid “arctic elephant.” Such a critter could play a key role in preserving the integrity of the permafrost layer, which currently fixes more CO2 than all of the world’s rainforests combined.From mammoths, George and I turn to the topic of synthetic meats, which could enter our kitchens and bellies much sooner than most people think.We close by discussing an ambitious longevity project currently underway in George’s lab.
Tech companies are always hoping to clear out the competition with their latest wearable.But Alphabet's life sciences division, Verily, is likely expecting a blow-out with this one.The company, formerly known as Google Life Sciences, has a patent-pending plan for a wirelessly connected “smart diaper” that would not only alert a caregiver when there’s a new “event” but also analyze and identify the fresh download—i.e., is it a number one or number two?But, Verily argues in its patent application, the market is lacking a convenient, affordable, all-in-one design that can differentiate between a wee squirt and a code brown.While both require attention and a change, a festering or explosive diaper bomb often requires more urgency, particularly if a baby is dealing with diaper rash.It filed the application in October of 2016, but it was just published recently by the US Patent and Trademark Office.
BioLabs, a scientist-entrepreneur and investor-founded network of shared lab workspaces, is managing operations.The facility has capacity for approximately 100 scientists and entrepreneurs; 19 companies have already moved in.Tufts Launchpad | BioLabs, located on the university's Health Sciences campus in downtown Boston, is a fully equipped, supported and permitted lab providing entrepreneurs with the technology and resources they need to accelerate development of their companies.It is outfitted with state-of-the art equipment and provides resident companies with access to Tufts' core facilities and services on a cost-effective, fee-for-service basis.Some of these services include sequencing, peptide synthesis, and confocal microscopy, as well as facilities for preclinical research.Pepducin-based therapeutics for the treatment of severe fibrotic diseases.
Beth Seidenberg joined Kleiner Perkins 13 years ago to focus on life sciences for the storied venture firm.Now, according to a Recode report, she’s heading off to start her own life sciences venture fund in L.A. where she lives.We’ve reached out to Kleiner and we’re awaiting more information.But the firm seemed to confirm the move to the outlet, reportedly noting that Seidenberg will continue to be a partner in Kleiner’s existing funds and stating that Kleiner remains committed to life sciences.While the move is interesting from a firm perspective — Kleiner has undergone one transition after another over the last half dozen years, parting ways with at least 10 investors, including Trae Vassallo, Mike Abbott, Chi-Hua Chien, Matt Murphy, and Aileen Lee — it’s perhaps even more interesting as part of an ongoing change to the broader industry.Whereas a decade or so ago, one held on to his or her role inside a venture fund by their fingernails if they had to, that’s no longer the case.
There’s no end to the number of fascinating devices and therapies being created right now in the fields of health and life sciences.The investors behind them are often pretty interesting, too, given the expertise needed to make informed bets on what are often completely unproven projects.Such is the case with Foresite Capital, a seven-year-old, San Francisco-based outfit that just closed on $668 million for its fourth venture fund, its biggest pool of capital so far.(Its first funds closed with $100 million, $300 million, and $450 million, respectively.)The firm was founded by Jim Tananbaum, who has started and sold healthcare companies and who earned the dubious distinction — courtesy of Bloomberg — of symbolizing what’s gone wrong with the Burning Man festival in recent years.(Months after Bloomberg described an elaborate camp he had built, Tananbaum, who in 2014 was elected to the board of the nonprofit that oversees the event, resigned.)
Heidelberg, New York, and Cold Spring Harbor, 3 April 2018 - EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press today announced the launch of Life Science Alliance, a new global, open access, editorially independent, peer-reviewed journal committed to rapid, fair, and transparent publication of valuable research from across the life sciences.The alliance between three distinguished academic publishing houses offers authors a new and attractive choice among not-for-profit, open access journals.Timely editorial decisions are made through collaborative consultation between the editorial team and leading academic scientists.Papers published in Life Science Alliance meet high scientific and editorial standards established by the alliance partners for new results.Life Science Alliance welcomes important confirmatory, negative, and refuting data, as well as community resources such as datasets, screens, and new methods.To increase the reproducibility of results and stimulate data sharing, Life Science Alliance encourages authors to publish source data alongside each figure.
Opentrons, a company that’s setting out to help life scientists automate many of their experiments using robotics, has raised $10 million in a seed funding round led by Khosla Ventures, with participation from Lerer Hippeau Ventures, Y Combinator Continuity Fund, and Jeff Kindler.Founded out of Brooklyn in 2013, Opentrons is one of a number of startups to garner investment for robots that “save” humans from having to carry out repetitive tasks themselves.Opentrons’ robots offer automation for any laboratory, though for now it’s targeting biologists with pipetting.The company said that its hardware and software is used by “70 percent of the top 10 largest pharmaceutical companies and 90 percent of top 50 biology research universities,” according to a statement issued by the company.In addition to a fresh tranche of funding, the Y Combinator alum also announced its new $4,000 OT-2 lab robot, which includes access to a pre-programmed library of protocols (procedural methods for carrying out experiments) and which is designed to cut down on the time it takes to set experiments up.Researchers can develop their own from scratch with a new visual design program called Protocol Designer, which basically allows anyone to create their own protocols to run on the OT-2 without having to write any code.
The new server was officially brought into operation during a conference at the University of Freiburg.Galaxy, an open source platform enabling the analysis of big data for life sciences, is available for use by scientists via an Internet browser.It does not require programming skills: all settings can be made using a graphical interface.Researchers throughout Europe have already made use of the service, which is coordinated in Freiburg."To date we have registered about 900 users from 55 work groups, and within a year roughly a million requests have been calculated on our server," reports Dr. Björn Grüning, who heads the Galaxy team at Freiburg.The possibilities of big data are fundamentally changing many research projects in the life sciences: manageablysized experiments are often replaced by analyses that represent hundreds of thousands of individual experiments.
Avro, a life sciences startup in Y Combinator’s current batch, is banking on a method to deliver medications to populations unable to swallow or chew — it will administer them through the skin.Starting with allergy medications, the startup is developing skin patches that release drugs commonly used in seasonal allergies for children.The patches act much like nicotine patches, which deliver nicotine to those trying to quit smoking, but can deliver a variety of drugs, such as allergy medications, through our body’s largest organ.Co-founder Shakir Lakhani, who suffers from both seasonal and food allergies himself, tells TechCrunch he wanted to start with allergy relief not just for personal reasons but because it’s an area where children are resistant to taking the medications already out there.“There’s medications that say they taste like banana but don’t really taste like banana, ” he said.“The drugs are also relatively safe so it’s something we can work with without being too worried.”
BETHESDA, Md., Jan. 30, 2018 - Looking for the latest life science research advances in heart health, cancer or early stage drug development?We've got all that and more coming up at the 2018 Experimental Biology meeting (EB 2018), the premier annual meeting of five scientific societies to be held April 21-25 in San Diego.With more than 14,000 attendees and hundreds of scientific sessions, EB 2018 is a research bonanza you won't want to miss.This year's meeting will include cutting-edge presentations on a wide array of topics, including:How inflammation contributes to neurological problemsThe microbiome's role in heart disease
After nearly a year, venture capitalists nabbed their first U.S. acquisition for more than a billion dollars.Nor was it a company on the list of known unicorns.No, the award for the first big exit in a really long time goes to Impact Biomedicines, a developer of cancer therapeutics that sold to pharma giant Celgene earlier this month.The deal, which includes $1.1 billion in cash and up to $5.9 billion in milestone payments, is all the more astounding given that it involved a pretty new startup.It was, in the words of Medicxi founder Kevin Johnson, the kind of exit where “everyone goes home with a balloon.”Yet while the Impact acquisition stands out for its size and speed, it’s by no means the only sizable life science transaction in recent months.